Yazar "Kaynar, Leylagül" için listeleme
-
Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey
Fıratlı Tuğlular, Ayşe Tülin; Pehlivan, Mustafa; Sönmez, Mehmet; Kabukçu Hacıoğlu, Sibel; Saydam, Güray; Ayyıldız, Orhan; Kaynar, Leylagül; Demirkan, Fatih; Beksaç, Meral (CIG Media Group, 2022)... -
Prognostic factors and intensive care outcome in post-transplant phase of hematopoietic stem cell transplantation intensive care outcome in hematopoietic stem cell transplantation
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Erdoğan, Cem; Kızılaslan, Deniz; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Springer India, 2023)Introduction To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care ... -
Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-beta 1, IFN-gamma, and TNF-alpha genes in chronic phase chronic myeloid leukemia
Pehlivan, Mustafa; Haydaroğlu Şahin, Handan; Pehlivan, Sacide; Özdilli, Kürşat; Kaynar, Leylagül; Savran Oğuz, Fatma; Sever, Tuğçe; Yılmaz, Mehmet; Eser, Bülent; Duvarcı Öğret, Yeliz; Kis, Cem; Okan, Vahap; Çetin, Mustafa; Carin, Mahmut (Mary Ann Liebert, Inc, 2014)The aim of this study was to explore the association between polymorphisms of five cytokine genes and clinical parameters in patients with Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) treated with imatinib. ... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ... -
Turkish acute lymphoblastic leukemia registry, retrospective phase data
Demirkan, Fatih; Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzin, Kadriye Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya (The American Society of Hematology, 2019)Background and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in ...